Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
about
Protective immunity against toxoplasmosis in mice induced by single-dose immunization with rSAG1/2 protein released from poly(lactide-co-glycolide) microparticlesIdentification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic miceNeedle-free injection of insulin powder: delivery efficiency and skin irritation assessment.An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMVCross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.Green synthesis and evaluation of silver nanoparticles as adjuvant in rabies veterinary vaccine.Recent advances in developing vaccines against Toxoplasma gondii: an update.An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.The study of H. pylori putative candidate factors for single- and multi-component vaccine development.Adjuvant effects mediated by the carbohydrate recognition domain of Agrocybe aegerita lectin interacting with avian influenza H9N2 viral surface glycosylated proteins.Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice.Effects of recombinant Agrocybe aegerita lectin as an immunoadjuvant on immune responses.The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells.Vaccine adjuvants: smart components to boost the immune system.Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses
P2860
Q28846409-AB8767B9-8E8A-4AC4-8AB3-6741A75A67B2Q30371303-FE4EDE51-8138-4EA1-A632-40A7E14FE441Q33855226-6AC648A3-CAD8-4A86-9917-D9C1F4C06676Q34360945-BB5B02FD-7A4D-4565-BF71-3EE0AA625D9FQ35144633-F8C45184-A054-49BC-BA80-0E971F8C4D38Q35772241-93F3800F-A236-49ED-9565-A8B61EFD8286Q37152369-9D45D0E1-B64D-4FA1-B67E-FE189A8B4465Q38607376-E40CFD2B-B30B-4165-9329-AE29A10B44F8Q39174792-4832B63E-3C36-4CF1-A812-67FEDBFF387DQ39350897-E8B5C81B-3E93-4939-91AC-2EC2CEB4401FQ40083668-302956F6-B31F-48CB-B842-054F77F62F87Q42193505-A0C35F9A-A47B-4659-9B6D-9DB8DAFD0CD9Q47598017-AA6EB42E-E597-45B4-B7C0-7E4C78A39BBCQ49343115-48636AA5-03A6-439E-80C0-CA19CCBF8EEAQ50063256-C304F5BE-EDE1-42E8-9546-E9C8517E3D46Q58751640-E0446287-D699-468B-B1F5-168850F47BE6
P2860
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
@en
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
@nl
type
label
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
@en
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
@nl
prefLabel
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
@en
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
@nl
P2093
P2860
P1476
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
@en
P2093
M Kannadasan
Mohammed M Safhi
N Sukumaran
S M Sivakumar
P2860
P304
P356
10.1016/J.JSPS.2011.06.003
P577
2011-06-25T00:00:00Z